載入中
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
前收盤價
US$2.54
+US$0.01 · +0.40%
盤中時間採用ET。市場資料可能有所延遲。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日內區間
目前US$2.54
52週區間
目前US$2.54
盤中時間採用ET。市場資料可能有所延遲。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日內區間
目前US$2.54
52週區間
目前US$2.54
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 1600萬 USD | — | — | — |
| 銷貨成本 | 2.48萬 USD | — | — | — | — |
| 毛利 | −2.48萬 USD | 1600萬 USD | — | — | — |
| 研究與開發 | 1078.04萬 USD | 489.69萬 USD | 402.7萬 USD | 344.89萬 USD | 535.03萬 USD |
| 銷售、一般及管理費用 | 574.51萬 USD | 554.23萬 USD | 466.31萬 USD | 827.8萬 USD | 532.36萬 USD |
| 營業費用 | 943.44萬 USD | 1148.97萬 USD | 1258.69萬 USD | 1230.95萬 USD | 1423.58萬 USD |
| 利息收入 | 89.4萬 USD | 125.28萬 USD | 17.4萬 USD | 5.69萬 USD | 1141 USD |
| 利息支出 | 2萬 USD | 2.14萬 USD | 1.11萬 USD | 8599 USD | 6851 USD |
| 折舊和攤銷 | 2.48萬 USD | 1.92萬 USD | 5.18萬 USD | 4.16萬 USD | 4.53萬 USD |
| 營業利益 | −945.92萬 USD | 451.03萬 USD | −1258.69萬 USD | −1230.95萬 USD | −1423.58萬 USD |
| 淨利 | −1083.52萬 USD | 359.47萬 USD | −1251.39萬 USD | −1358.36萬 USD | −1377.07萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
Vanguard Extended Market ETFVXF5.52萬0.00%954億 USD0.05%US$235+0.80%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9846.730.00%61.81億 USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC8810.10.00%885.96億 USD0.21%US$45.33+0.49%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR3950.740.00%455.91億 USD0.17%US$84.44+0.44%
Dimensional - US Sustainability Core 1 ETFDFSU3087.30.00%23.92億 USD0.15%US$48.11+0.48%Vanguard Extended Market ETFVXFU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
